News + Filings Transactions
|
Mammen Mathai
Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
06/14/2023 | 10x Genomics, Inc. | TXG | Grant | Class A Common Stock | 1.9k | $0.00 | $0 | | 06/14/2023 |
06/14/2023 | 10x Genomics, Inc. | TXG | Grant | Stock Option (right to buy) | 4.7k | $57.62 | $268.6k | | 06/14/2023 |
05/11/2023 | 10x Genomics, Inc. | TXG | Sale | Class A Common Stock | 33k | $52.82 | $1.7M | | 05/11/2023 |
05/11/2023 | 10x Genomics, Inc. | TXG | Exercise | Stock Option (right to buy) | 200k | $1.16 | $232k | | 05/11/2023 |
06/15/2022 | 10x Genomics, Inc. | TXG | Grant | Class A Common Stock | 2.1k | $0.00 | $0 | | 06/15/2022 |
06/15/2022 | 10x Genomics, Inc. | TXG | Grant | Stock Option (right to buy) | 5.3k | $39.62 | $210k | | 06/15/2022 |
02/15/2022 | JOHNSON & JOHNSON | JNJ | Exercise | Performance Share Units | 7.7k | $0.00 | $0 | | 02/14/2022 |
02/15/2022 | JOHNSON & JOHNSON | JNJ | Payment of Exercise | Common Stock | 3.4k | $165.89 | $558.4k | | 02/14/2022 |
02/14/2022 | JOHNSON & JOHNSON | JNJ | Grant | | 38.7k | $165.89 | $6.4M | | 02/14/2022 |
02/14/2022 | JOHNSON & JOHNSON | JNJ | Exercise | Restricted Share Units | 7.4k | $0.00 | $0 | | 02/14/2022 |
02/14/2022 | JOHNSON & JOHNSON | JNJ | Payment of Exercise | Common Stock | 2.3k | $168.85 | $394.3k | | 02/14/2022 |
02/14/2022 | JOHNSON & JOHNSON | JNJ | Grant | Restricted Share Units | 3.9k | $0.00 | $0 | | 02/14/2022 |
06/11/2021 | 10x Genomics, Inc. | TXG | Grant | Class A Common Stock | 625 | $0.00 | $0 | | 06/11/2021 |
06/11/2021 | 10x Genomics, Inc. | TXG | Grant | Stock Option (right to buy) | 1.6k | $193.51 | $302.5k | | 06/11/2021 |
06/15/2020 | 10x Genomics, Inc. | TXG | Grant | Stock Option (right to buy) | 4.4k | $88.42 | $391.9k | | 06/15/2020 |
09/16/2019 | 10x Genomics, Inc. | TXG | Other (disposition) | Stock Option (right to buy) | 200k | $1.16 | $232k | | 09/16/2019 |
09/16/2019 | 10x Genomics, Inc. | TXG | Other (acquisition) | Stock Option (right to buy) | 200k | $1.16 | $232k | | 09/16/2019 |
03/15/2016 | Theravance Biopharma, Inc. | TBPH | Grant | Ordinary Shares | 90k | $0.00 | $0 | | 03/15/2016 |
02/20/2016 | Theravance Biopharma, Inc. | TBPH | Payment of Exercise | Ordinary Shares | 19.8k | $15.65 | $310.6k | | 02/20/2016 |
11/20/2015 | Theravance Biopharma, Inc. | TBPH | Payment of Exercise | Ordinary Shares | 934 | $17.17 | $16k | | 11/20/2015 |
08/20/2015 | Theravance Biopharma, Inc. | TBPH | Payment of Exercise | Ordinary Shares | 934 | $12.98 | $12.1k | | 08/20/2015 |
06/02/2015 | Theravance Biopharma, Inc. | TBPH | Payment of Exercise | Ordinary Shares | 7.4k | $13.83 | $101.8k | | 06/02/2015 |
05/20/2015 | Theravance Biopharma, Inc. | TBPH | Payment of Exercise | Ordinary Shares | 673 | $14.24 | $9.6k | | 05/20/2015 |
02/20/2015 | Theravance Biopharma, Inc. | TBPH | Payment of Exercise | Ordinary Shares | 674 | $19.52 | $13.2k | | 02/20/2015 |
02/05/2015 | Theravance Biopharma, Inc. | TBPH | Grant | Ordinary Shares | 130k | $0.00 | $0 | | 02/05/2015 |
11/20/2014 | Theravance Biopharma, Inc. | TBPH | Payment of Exercise | Common Stock | 658 | $0.00 | $0 | | 11/20/2014 |
10/08/2014 | Theravance Biopharma, Inc. | TBPH | Grant | Share Option (Right to Buy) | 170k | $22.00 | $3.7M | | 10/08/2014 |
08/20/2014 | Innoviva, Inc. | INVA | Payment of Exercise | Common Stock | 3.3k | $22.76 | $74.2k | | 08/20/2014 |
06/16/2014 | Innoviva, Inc. | INVA | Grant | Common Stock | 28.4k | $0.00 | $0 | | 06/16/2014 |
06/02/2014 | Innoviva, Inc. | INVA | Grant | Common Stock | 50k | $0.00 | $0 | | 06/02/2014 |
06/02/2014 | Innoviva, Inc. | INVA | Grant | Common Stock | 50k | $0.00 | $0 | | 06/02/2014 |
06/02/2014 | Innoviva, Inc. | INVA | Grant | Common Stock | 21k | $0.00 | $0 | | 06/02/2014 |
05/09/2014 | Innoviva, Inc. | INVA | Payment of Exercise | Common Stock | 22.8k | $26.86 | $613.3k | | 05/09/2014 |
04/27/2014 | Innoviva, Inc. | INVA | Grant | Common Stock | 37.5k | $0.00 | $0 | | 04/27/2014 |
03/13/2014 | Innoviva, Inc. | INVA | Gift | Common Stock | 1.2k | $0.00 | $0 | | 05/09/2014 |
|
|